Jane Street Group LLC Acquires 5,053 Shares of CVRx, Inc. (NASDAQ:CVRX)

Jane Street Group LLC boosted its holdings in CVRx, Inc. (NASDAQ:CVRX) by 36.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,038 shares of the company’s stock after acquiring an additional 5,053 shares during the quarter. Jane Street Group LLC owned 0.08% of CVRx worth $168,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in CVRX. Parkman Healthcare Partners LLC lifted its position in CVRx by 52.6% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 682,897 shares of the company’s stock valued at $6,016,000 after acquiring an additional 235,277 shares in the last quarter. PDT Partners LLC purchased a new stake in CVRx in the 3rd quarter valued at about $543,000. Marshall Wace LLP purchased a new stake in CVRx in the 2nd quarter valued at about $495,000. International Assets Investment Management LLC purchased a new stake in CVRx in the 3rd quarter valued at about $338,000. Finally, State Street Corp increased its stake in CVRx by 11.4% in the 3rd quarter. State Street Corp now owns 264,733 shares of the company’s stock valued at $2,332,000 after buying an additional 27,071 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

CVRx Trading Up 6.1 %

Shares of CVRX stock opened at $15.04 on Tuesday. The company has a 50 day moving average of $14.00 and a 200-day moving average of $10.97. The company has a quick ratio of 10.23, a current ratio of 11.32 and a debt-to-equity ratio of 0.76. CVRx, Inc. has a 12-month low of $6.40 and a 12-month high of $29.23. The firm has a market cap of $364.87 million, a P/E ratio of -5.57 and a beta of 1.20.

CVRx (NASDAQ:CVRX) last released its quarterly earnings data on Tuesday, October 29th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.12). CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%. The business had revenue of $13.37 million during the quarter, compared to the consensus estimate of $13.28 million. During the same period last year, the business posted ($0.43) earnings per share. Sell-side analysts anticipate that CVRx, Inc. will post -2.62 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CVRX shares. Lake Street Capital increased their price objective on shares of CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up previously from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $14.00 price objective on shares of CVRx in a research note on Wednesday, October 23rd. Canaccord Genuity Group increased their price objective on shares of CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, Craig Hallum raised their price target on shares of CVRx from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.67.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.